Mithra Pharmaceuticals S.A.

MITRA

BE0974283153

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 09:06:44 2024-04-25 am EDT			5-day change	1st Jan Change
0.222 ^EUR	+0.23%		-4.72%	-82.30%

Apr. 22	Mithra Pharmaceuticals Obtains Court Protection Measures	MT
Mar. 08	Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mithra Pharmaceuticals S A : Adjustment to the rights of the holders of convertible bonds

September 02, 2022 at 12:09 pm EDT

Liege, Belgium, 02 September 2022 - 17:45 CET - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces today that, as a result of the senior secured convertible facilities agreement and conversion agreement entered into by the Company and announced on 8 August 2022, and in accordance with condition 5(b) of the Company's EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855), the conversion price of the bonds has been adjusted from EUR 25.1917 to EUR 24.5425, effective as of 8 August 2022.

Read the press release

Attachments

Original Link
Original Document
Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 02 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2022 16:08:01 UTC.

Latest news about Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals Obtains Court Protection Measures	Apr. 22	MT
Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business	Mar. 05	MT
Mithra Pharmaceuticals Terminates CEO; Names CFO, COO as Successors	Mar. 05	MT
Mithra Pharmaceuticals SA Announces CEO Changes	Mar. 05	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Mithra: share price falls, financial visibility reduced	Feb. 06	CF
Mithra : Goldman Sachs reduces its stake to below 3%.	Dec. 27	CF
Mithra Pharmaceuticals Completes Pediatric Study of Contraceptive Product in Adolescent Women	Dec. 21	MT
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China	Dec. 04	MT
Mithra Pharmaceuticals SA and Gedeon Richter Plc. Signs Binding Head of Terms to Commercialize Estelle and Donesta in China	Dec. 04	CI
Mithra Pharmaceuticals to Conduct Additional Data Analysis for Menopause-candidate Drug	Nov. 30	MT
Certain Ordinary Shares of Mithra Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	Nov. 25	CI
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mithra and Searchlight Pharma Sign DONESTA Licensing Agreement for Canada	23-10-26	CI
Mithra Pharmaceuticals Signs License Agreement for Menopause Drug With Canada's Searchlight Pharma	23-10-26	MT
Mithra and Searchlight Pharma Inc. Signs License and Supply Agreement for the Canadian Rights to DONESTA	23-10-26	CI
Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23-10-23	MT
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023	23-09-27	CI
Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Mithra Pharmaceuticals SA(ENXTBR:MITRA) dropped from S&P Global BMI Index	23-09-18	CI
Mithra Pharmaceuticals Raises EUR20 Million in Private Placement	23-08-29	MT
Mithra Pharmaceuticals SA announced that it has received ?20 million in funding from Armistice Capital, LLC	23-08-27	CI

Chart Mithra Pharmaceuticals S.A.

Duration

Period

More charts

Company Profile

Mithra Pharmaceuticals S.A. is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Mithra Pharmaceuticals S.A.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.2215 EUR

Average target price

0.11 EUR

Spread / Average Target

-50.34%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MITHRA PHARMACEUTICALS S.A.	-82.30%	16.36M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.46%	29.36B
UCB	+57.29%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-11.83%	17.31B
INCYTE CORPORATION	-17.69%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.47%	8.31B

Biopharmaceuticals